Welcome to our dedicated page for Anika Therapeutics news (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics stock.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global joint preservation company focused on early intervention orthopedics, osteoarthritis (OA) pain management, and regenerative solutions based on hyaluronic acid and implant technologies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Anika’s clinical programs, product portfolio, and financial performance evolve over time.
News about Anika commonly covers quarterly and annual financial results, including performance in its Commercial Channel and OEM Channel, as well as commentary on operating expenses, cost-saving measures, and capital allocation decisions such as share repurchase programs. Investors can also find updates on governance and compensation topics, including amendments to equity incentive plans and inducement grants made under Nasdaq Listing Rule 5635(c)(4).
A significant portion of Anika’s news flow focuses on clinical and regulatory milestones for its key products. Examples include updates on the U.S. pivotal Phase III FastTRACK study for the Hyalofast cartilage repair scaffold, the filing of the third and final PMA module for Hyalofast with the U.S. Food and Drug Administration, and progress toward a U.S. New Drug Application for Cingal, the company’s non-opioid, single-injection OA pain management product. Releases also describe commercial milestones, such as Cingal surpassing one million injections worldwide and the growth trajectory of the Integrity Implant System.
Corporate and leadership developments are another recurring theme. Anika issues press releases on planned leadership transitions, board changes, and strategic refocusing around its hyaluronic acid portfolio and regenerative solutions. By reviewing the ANIK news stream on this page, readers can monitor how clinical data, regulatory submissions, commercial performance, and governance actions shape the company’s position in osteoarthritis pain management and orthopedic regenerative medicine.
Summary not available.
Anika Therapeutics, a leader in early intervention orthopedics, announced it will release its first quarter 2023 financial results on May 9, 2023, after market close. The company will host a conference call at 5:00 p.m. ET on the same day to discuss the financial results and key business highlights. Investors can join the conference call by dialing the toll-free number or through an audio webcast available on Anika's website. Anika focuses on joint preservation and minimally invasive orthopedic solutions, addressing areas such as Osteoarthritis Pain Management and Regenerative Solutions, enhancing active living for individuals worldwide.
On April 13, 2023, Anika Therapeutics (NASDAQ: ANIK) announced significant corporate developments, including the appointment of Gary Fischetti as a Class III director as part of a cooperation agreement with Caligan Partners LP. The company also formed a new Capital Allocation Committee to enhance management's capital allocation strategies. Anika's Board has authorized a $20 million share repurchase program, which includes $5 million through an accelerated repurchase program and another $5 million over the next 12 months in open market purchases, contingent upon cash flow. The remaining $10 million will also be purchased in the open market, subject to positive cash flow. CEO Cheryl Blanchard expressed confidence in the agreement, emphasizing long-term shareholder value creation as a priority.
Anika Therapeutics, Inc. (NASDAQ: ANIK), a leader in joint preservation and early intervention orthopedics, will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023. The management team will host a virtual presentation, which begins at 12:45 PM ET, followed by a Q&A session. Investors can access a webcast of the presentation in the Investor Relations section of Anika’s website, with an archived version available post-event. Anika specializes in innovative products for osteoarthritis pain management, regenerative solutions, and sports medicine. With its headquarters located near Boston, Anika strives to enhance active living through minimally invasive orthopedic solutions.
Anika Therapeutics (NASDAQ: ANIK) has received FDA clearance for its Tactoset Injectable Bone Substitute to be combined with autologous bone marrow aspirate (BMA), enhancing its regenerative capabilities. This new indication allows for the treatment of bone defects including insufficiency fractures and cysts, expanding Tactoset's commercial reach. Anika has also entered into a distribution agreement for the Marrow Cellution Bone Marrow Aspiration Needle in the U.S., which increases cell recovery efficiency. Additionally, new, enhanced Tactoset delivery cannulas have been launched, improving surgical targeting and ease of use, particularly in foot and ankle procedures.
Anika Therapeutics (NASDAQ: ANIK) has filed preliminary proxy materials with the SEC related to its 2023 Annual Meeting of Stockholders. The date of the meeting is yet to be scheduled. The Board recommends re-electing nominees John Henneman, III and Susan Vogt, both of whom joined as part of a Board refreshment process. Anika has significantly expanded its market opportunity from $1 billion to over $8 billion, focusing on joint preservation in early intervention orthopedics. However, a shareholder, Caligan Partners LP, has proposed candidates for the Board, advocating for a strategic review and potential sale of the company, which the Board believes could harm shareholder value.
Anika Therapeutics, a global leader in joint preservation, has announced its participation in the Sidoti Small Cap Virtual Investor Conference on March 22, 2023, at 9:15 AM ET. The event will feature a virtual presentation from management, followed by a Q&A session. Interested investors can access the webcast through Anika's Investor Relations section on their website, where an archive of the presentation will also be made available. Anika focuses on early intervention orthopedic care, offering innovative solutions for osteoarthritis pain management and soft tissue repair.
Anika Therapeutics (NASDAQ: ANIK) recently showcased its innovative products at the 2023 AAOS Annual Meeting in Las Vegas, highlighting the full market release of the X-Twist Fixation System and the limited market release of the RevoMotion Reverse Shoulder Arthroplasty System. These products enhance joint preservation and restoration techniques. The Tactoset Injectable Bone Substitute and OVOMotion Total Shoulder Arthroplasty System were also featured, demonstrating advancements in orthopedic solutions. CEO Cheryl R. Blanchard emphasized commitment to delivering a robust product portfolio addressing surgeons' evolving needs.
Anika Therapeutics reported a strong fourth quarter with revenue growth of 11% to $39.6 million and full-year revenue growth of 6% to $156.2 million. Notable increases were seen in Osteoarthritis Pain Management, with revenues reaching $23.7 million (20% growth). The company commenced the limited market release of the RevoMotion Reverse Shoulder Arthroplasty System and fully launched the X-Twist Fixation System. Anika's Hyalofast product is nearing full enrollment in its pivotal Phase III trial, while the FDA has designated it as a Breakthrough Device. For 2023, Anika expects revenue between $158 million and $163 million, reflecting modest growth amid various product reclassifications.
Anika Therapeutics (NASDAQ: ANIK) has announced its participation in the Canaccord Genuity Musculoskeletal Conference in Las Vegas on March 7, 2023, at 3:00 p.m. PT (6:00 p.m. ET). The conference is aimed at showcasing advancements in early intervention orthopedics, a field where Anika specializes. A live audio webcast will be accessible via the Investor Relations section on Anika's official website, www.anika.com. Additionally, an audio archive of the session will be available afterward, providing further insights into the company's innovative products and strategies.